Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Aksjekurs
$0.00185055
Markedsverdi
$48.29K
Endring (1 dag)
-3.55%
Endring (1 år)
30.31%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Healthcare
P/B-forhold for Nuformix plc (NFX)
P/B-forhold per September 2026 TTM: 2.01
Ifølge Nuformix plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 2.01. Ved slutten av 2024 hadde selskapet et P/B-forhold på 0.64.
P/B-historikk for Nuformix plc fra 2014 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 2.01 -61.14%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 224.23%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 327.62%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 98.95%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 268.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH